Core Insights - JD Health and Hangzhou Minsheng Health Pharmaceutical Co., Ltd. signed a strategic cooperation agreement to develop patient-centered health management solutions covering the entire disease cycle [1] - The partnership aims to leverage each other's strengths in branding, products, channels, technology, and professional services to enhance the accessibility and trust in high-quality health products and services for patients [1] Group 1: Strategic Cooperation - JD Health and Hangzhou Minsheng Health Pharmaceutical will explore collaboration in drug development, digital marketing, and patient education [1] - The cooperation is expected to accelerate the nationwide distribution of quality health products and services [1] - Hangzhou Minsheng Health Pharmaceutical values JD Health's comprehensive channel layout and professional medical service resources [1] Group 2: New Product Launch - Hangzhou Minsheng Health Pharmaceutical launched a new smoking cessation drug, Varenicline Tartrate Tablets (brand name: Minsheng Lesuke), on JD Health [2] - The product features a 0.5mg mini tablet design for easy dosage adjustment, particularly suitable for elderly and sensitive populations [2] - Advanced packaging technology ensures drug stability and helps improve patient adherence to treatment [2] Group 3: Industry Development - JD Health is committed to enhancing the scientific smoking cessation ecosystem through industry collaboration [3] - The company plans to utilize its full-channel supply chain and healthcare service advantages to provide quality smoking cessation products [3] - JD Health aims to promote the widespread application of scientific smoking cessation methods in partnership with Hangzhou Minsheng Health Pharmaceutical [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.23% on November 20, with Minsheng Health leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hainan Haiyao (000566) with a closing price of 7.92, up 10.00% and a trading volume of 2.1875 million shares, totaling 1.634 billion yuan [1] - Kangyi Pharmaceutical (300086) closed at 12.15, up 8.97% with a trading volume of 1.4039 million shares, totaling 1.656 billion yuan [1] - Other significant gainers included Bibete (688759), Yuekang Pharmaceutical (688658), and Qianyan Bio (688221) with increases ranging from 5.43% to 7.73% [1] - Conversely, the following stocks faced declines: - Minsheng Health (301507) closed at 16.69, down 6.18% with a trading volume of 273,400 shares, totaling 463 million yuan [2] - Shanhua Pharmaceutical (300452) and Hasa Lian (002900) also saw declines of 4.45% and 4.12% respectively [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.233 billion yuan from institutional investors, while retail investors contributed a net inflow of 964 million yuan [2] - Notable capital flows included: - Hainan Haiyao (000566) had a net inflow of 25.3 million yuan from institutional investors, but a net outflow of 101 million yuan from retail investors [3] - Kangyi Pharmaceutical (300086) experienced a net inflow of 56.4 million yuan from institutional investors, while retail investors saw a net outflow of 67.9 million yuan [3]

Core Points - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. has signed a strategic cooperation agreement with JD Health on November 19, 2023 [1] - The company's smoking cessation drug, Minsheng Lesuke (Varenicline Tartrate Tablets), will be launched exclusively on JD Health [1] Company Summary - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. is focusing on expanding its market presence through strategic partnerships [1] - The collaboration with JD Health signifies a move towards leveraging e-commerce platforms for product distribution [1] Industry Summary - The smoking cessation market is seeing increased attention with the introduction of specialized medications [1] - E-commerce is becoming a vital channel for pharmaceutical companies to reach consumers effectively [1]

Core Viewpoint - Minsheng Health is in the initial stage of launching its new smoking cessation drug, Minsheng Lesuke Tartrate Varenicline Tablets, and is utilizing multiple channels for promotion, including e-commerce platforms and offline pharmacies [1] Group 1: Product Launch and Promotion - The new smoking cessation product is currently available for pre-sale on online platforms such as JD Health and Alibaba Health, with ongoing efforts to launch in offline pharmacies [1] - The company is collaborating with authoritative smoking cessation organizations to conduct educational initiatives aimed at enhancing consumer health awareness [1] Group 2: Future Initiatives and Collaborations - In November 2025, the company plans to co-establish a Health Promotion Professional Committee with the China Tobacco Control and Health Association [1] - The company aims to actively participate in public health services by collaborating with relevant authoritative institutions to advance academic research, standard setting, and health education, contributing to a more comprehensive smoking control system [1]

Core Viewpoint - Minsheng Health is in the initial stage of launching its new smoking cessation product, Minsheng Lesuke, which is currently available for pre-sale on various e-commerce platforms and is gradually being introduced in offline pharmacies [1] Group 1: Product Launch and Promotion - The new product, Minsheng Lesuke (varenicline tartrate), is being promoted through multiple channels including e-commerce platforms and offline pharmacies [1] - The product has officially started pre-sale on platforms such as JD Health and Alibaba Health, with ongoing efforts to list it in offline pharmacies [1] Group 2: Collaboration and Health Education - The company is collaborating with authoritative smoking cessation organizations to conduct educational initiatives aimed at enhancing consumer health awareness [1] - In August 2025, the company, in partnership with the China Smoking Control Association, released the "China Clinical Smoking Cessation Expert Consensus Gold Standard (2025 Updated Version)" [1] - In November 2025, the company co-founded a Health Promotion Professional Committee with the China Smoking Control and Health Association [1] Group 3: Commitment to Public Health - As an active participant in public health services, the company plans to collaborate with relevant authoritative institutions to advance academic research, standard formulation, and health education [1] - The company aims to contribute to the establishment of a more comprehensive smoking control system and support the construction of a healthy China through its pharmaceutical efforts [1]

二是稳步提高医保报销水平。目前，参保居民、职工住院使用报销范围内的药品、耗材等，分别可以享 受到70%左右、80%以上的报销待遇。不断健全门诊慢特病保障政策，统一将恶性肿瘤门诊治疗、肾透 析等门诊维持治疗周期长、医疗费用相对较高的81种慢性病，纳入门诊慢特病保障范围，参照住院报销 政策予以保障，减轻了患者大额门诊医疗费用负担。同时，全面建立普通门诊报销制度，参保群众因头 痛脑热、感冒发烧、腹泻等常见病、多发病发生的日常门诊费用，也能享受报销待遇，比如，城乡参保 居民在基层医疗机构发生的报销范围内的普通门诊费用，可以报销65%，城乡居民诊断为高血压、糖尿 病后，购买降压药、降糖药还能享受到75%的专项报销待遇。 三是完善大病保险和医疗救助政策。统一居民大病保险起付标准，分段报销比例均达到60%以上，一个 医疗年度内最高可报销40万元。特困人员、低保对象、返贫致贫人口、低保边缘家庭成员和防止返贫监 测帮扶对象等困难群众，可享受居民医保个人缴费部分补贴和医疗费用救助，年度救助限额提高到5万 元以上。"十四五"期间，医疗救助对象累计就医4292.02万人次，医保基金支付544.35亿元。 四是持续完善生育医疗费用报销 ...

Core Insights - The overall gross margin changes for the company are primarily influenced by product structure and channel variations, with no cost-related factors affecting gross margin levels [1] - The vitamin and mineral product category represents the highest revenue share for the company, with the main product, 21 Jin Weita multi-element tablets, maintaining a normal gross margin level [1] - The growth rate of vitamin and mineral health foods and functional foods has outpaced that of OTC vitamin and mineral products in recent years, leading to a decline in overall gross margin [1] - The company anticipates that the overall gross margin will gradually improve with the increase in sales scale of new products and the growth of self-operated businesses [1] Product Development and Market Potential - The company has recently obtained approval for varenicline tartrate tablets, which are used for smoking cessation, indicating a strategic move into the smoking cessation market [1] - The domestic approval for varenicline tablets has been obtained in recent years, and sales are gradually increasing, with significant market potential due to the large number of smokers in China [2] - The company expects that the introduction of new products, such as varenicline and minoxidil solution, will involve certain costs but will not significantly impact the overall sales expense ratio and profit situation [2]

Core Viewpoint - Minsheng Health announced on November 17 that its product, Lesuke, features innovative packaging designs aimed at enhancing user experience and medication adherence [1] Group 1: Packaging Design - The outer packaging of Lesuke uses warm color tones to convey a positive and cheerful message, complemented by high-recognition design symbols for better user memory [1] - The inner packaging employs dual aluminum high-barrier packaging, significantly outperforming traditional aluminum-plastic blister packs in oxygen and light barrier performance, ensuring stable drug efficacy [1] - Design details in the inner packaging help users understand complex usage methods, including easy-tear lines for convenience during travel, enhancing overall user experience [1] Group 2: Dosage and User Support - Lesuke is available in a 0.5mg small dosage, making it easier to swallow and allowing for flexible dosage adjustments, which is particularly beneficial for elderly users [1] - To support users in creating a smoke-free environment, the company has developed a proprietary scientific smoking cessation app that offers medication tracking, progress monitoring, and professional follow-up services throughout the cessation process [1]

证券日报网讯 民生健康11月17日发布公告，在公司回答调研者提问时表示，公司控股股东是杭州民生 药业股份有限公司，民生药业创建于1926年，一直专注于西药制药产业，现阶段致力于四大产品管线： 肝病领域产品线，慢性病领域产品线、眼科及皮肤外用药领域产品线和以血液肿瘤为主的专科领域产品 线。 （编辑 袁冠琳） ...

Core Viewpoint - Minsheng Health announced on November 17 that its vitamin and mineral segment is expected to maintain steady growth due to continuous new product launches in both online and offline channels, as well as deepening offline channel engagement and expanding online channel reach [1] Group 1 - The company will continue to launch new products in both online and offline channels [1] - The company aims to expand product coverage through deepening offline channels and expanding online channels [1]